Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Anavex Life Sciences Corp AVXL

Healthcare Biotechnology
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of... see more

Recent & Breaking News (NDAQ:AVXL)

Anavex Life Sciences Reports Fiscal Year 2018 Financial Results And Provides Clinical Study Update

GlobeNewswire December 12, 2018

Anavex Life Sciences to Announce 2018 Fiscal Year End Financial Results on Wednesday, December 12, 2018

GlobeNewswire December 10, 2018

Anavex Life Sciences Strengthens its Scientific Advisory Board with Distinguished Researcher for Clinical Treatment of Parkinson’s Disease Dementia (PDD)

GlobeNewswire November 8, 2018

Report: Developing Opportunities within Stryker, Anavex Life Sciences, Engility, Baker Hughes, a GE company, GlycoMimetics, and HCP — Future Expectations, Projections Moving into 2018

GlobeNewswire November 6, 2018

First Patient Enrolled in Anavex Life Sciences Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Parkinson’s Disease Dementia (PDD)

GlobeNewswire October 30, 2018

Anavex Life Sciences Presents New Three-Year, Longitudinal Clinical Efficacy Data for ANAVEX®2-73 in Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

GlobeNewswire October 26, 2018

Anavex Life Sciences Announces FDA Approval of IND for Phase 2 Trial of ANAVEX®2-73 in Patients with Rett Syndrome

GlobeNewswire October 19, 2018

Report: Exploring Fundamental Drivers Behind Monroe Capital, Anavex Life Sciences, Haynes International, Atara Biotherapeutics, Lands' End, and Envestnet — New Horizons, Emerging Trends, and Upcoming Developments

GlobeNewswire October 16, 2018

Anavex Life Sciences to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference

GlobeNewswire September 26, 2018

First Patient Enrolled in Anavex Life Sciences Phase 2b/3 Clinical Trial of ANAVEX®2-73 for the Treatment of Early Alzheimer’s Disease

GlobeNewswire August 28, 2018

Investor Expectations to Drive Momentum within Capital Senior Living, Thermon Group, L.B. Foster, Anavex Life Sciences, Opiant Pharmaceuticals, and Huron Consulting Group — Discovering Underlying Factors of Influence

GlobeNewswire August 16, 2018

Anavex Life Sciences Reports Fiscal Third Quarter 2018 Financial Results

GlobeNewswire August 9, 2018

Anavex Life Sciences to Announce Fiscal Third Quarter 2018 Financial Results on Thursday, August 9, 2018

GlobeNewswire August 7, 2018

Investor Expectations to Drive Momentum within NetApp, eBay, The Boeing, HCP, Atossa Genetics, and Anavex Life Sciences — Discovering Underlying Factors of Influence

GlobeNewswire July 30, 2018

Anavex Life Sciences Presents New Data Identifying Treatment Response Biomarkers in Alzheimer’s Disease Patients Treated with Investigational ANAVEX®2-73 at 2018 Alzheimer’s Association International Conference (AAIC)

GlobeNewswire July 25, 2018

Anavex Life Sciences Receives Approval to Initiate Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Parkinson’s Disease Dementia

GlobeNewswire July 9, 2018

Anavex Life Sciences Receives Approval To Initiate Phase 2b/3 Clinical Trial of ANAVEX®2-73 for the Treatment of Early Alzheimer’s Disease

GlobeNewswire July 3, 2018

Anavex Life Sciences Reports Fiscal Second Quarter 2018 Financial Results

GlobeNewswire May 10, 2018

Anavex Life Sciences to Announce Fiscal Second Quarter 2018 Financial Results on Thursday, May 10, 2018

GlobeNewswire May 9, 2018

27 Stocks Moving In Tuesday's Mid-Day Session

Benzinga.com  April 17, 2018